{"groups":[{"description":"Participants received pembrolizumab 10 mg/kg intravenously (IV) over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. Qualified participants who completed the first course of pembrolizumab treatment but progressed after discontinuation were eligible for a second course of pembrolizumab at 10 mg/kg IV Q2W for up to \\~1 additional year, at the Investigator's discretion. Per protocol participants were presented by treatment received in the single arm study.","id":"FG000","title":"Pembrolizumab 10 mg/kg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"31"}],"type":"Sponsor Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"43"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"391"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"477"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"475"}],"type":"Treated During First Course"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"Treated During Second Course"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"477"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Per protocol, response/progression or adverse events during the second pembrolizumab course were not counted towards efficacy outcome measures or safety outcome measures respectively.\n\nPer protocol, analyses of disease type cohort was planned and conducted for efficacy outcome measures only.","recruitmentDetails":"Participants with a histologically- or cytologically-confirmed diagnosis of 20 advanced (unresectable and/or metastatic) solid tumors, were recruited into a single arm."}